Edition:
United States

Alimera Sciences Inc (ALIM.O)

ALIM.O on Consolidated Issue listed on NASDAQ Global Market

1.23USD
23 Feb 2017
Change (% chg)

$-0.05 (-3.91%)
Prev Close
$1.28
Open
$1.26
Day's High
$1.27
Day's Low
$1.20
Volume
1,037,794
Avg. Vol
410,972
52-wk High
$5.15
52-wk Low
$1.01

Latest Key Developments (Source: Significant Developments)

Alimera Sciences and Knight Therapeutics file new drug submission for iluvien in Canada
Wednesday, 22 Feb 2017 08:00am EST 

Alimera Sciences Inc : Alimera Sciences and Knight Therapeutics announce filing of new drug submission for iluvien in Canada .Alimera Sciences Inc - Knight's new drug submission (NDS) for iluvien has been accepted for review by Health Canada.  Full Article

Stonepine Capital LP reports 5.4 pct passive stake in Alimera Sciences
Thursday, 17 Nov 2016 02:42pm EST 

Alimera Sciences Inc :Stonepine Capital LP reports 5.4 percent passive stake in Alimera Sciences Inc as of Nov 7 - sec filing.  Full Article

Great point reports 5.12 pct passive stake in Alimera Sciences - SEC filing
Monday, 22 Aug 2016 04:41pm EDT 

Alimera Sciences Inc :Great Point Partners Llc reports 5.12 percent passive stake in alimera sciences inc as of Aug. 11 - sec filing.  Full Article

Alimera Sciences prices public offering of common stock
Thursday, 11 Aug 2016 08:41am EDT 

Alimera Sciences Inc : Alimera Sciences prices public offering of common stock .Says public offering of 18.0 million common shares priced at $1.40per share.  Full Article

Alimera Sciences proposes public offering of common stock
Wednesday, 10 Aug 2016 04:01pm EDT 

Alimera Sciences Inc : Alimera Sciences proposes public offering of common stock .All shares in offering are to be sold by Alimera, with net proceeds to be used to fund continued commercialization of Iluvien.  Full Article

Alimera Sciences Q2 GAAP loss per share $0.15
Wednesday, 3 Aug 2016 05:41pm EDT 

Alimera Sciences Inc : Alimera sciences announces second quarter 2016 financial results and provides business update . Q2 gaap loss per share $0.15 . Q2 adjusted non-gaap loss per share $0.17 . Q2 revenue rose 66 percent to $9.6 million . Alimera sciences inc says has engaged in discussions with fda regarding potential future indications for iluvien .Based on discussions, believes it should be able to establish adequate evidence of safety and efficacy for approval of iluvien for additional indication.  Full Article

Alimera Sciences sees Q2 revenue of $9.3 mln - $9.5 mln
Tuesday, 26 Jul 2016 07:30am EDT 

Alimera Sciences Inc: Announces record second quarter 2016 revenue . Sees Q2 2016 revenue $9.3 million to $9.5 million . Says modified liquidity and revenue covenants in its existing loan agreement with Hercules Capital Inc . Says modification allows for reduction of Alimera's liquidity threshold . Q2 revenue view $7.2 million -- Thomson Reuters I/B/E/S . Says modifies its liquidity and revenue covenants under its loan facility . Says Q2 2016 u.s. Revenue is expected to be in range of $7.0 million to $7.2 million .Says modification reduces Co's trailing three-month revenue requirement through period ending August 31, 2016.  Full Article

Alimera Sciences signs Knight Therapeutics as distributor for Canada
Tuesday, 21 Jul 2015 07:30am EDT 

Alimera Sciences Inc:Says signs Knight Therapeutics as exclusive iluvien® distributor for Canada.Says Knight will also handle all regulatory and commercial activities for iluvien in Canada.  Full Article

Alimera Sciences Inc's ILUVIEN receives 17th european marketing authorization
Tuesday, 14 Apr 2015 08:00am EDT 

Alimera Sciences Inc:Says that marketing authorization has been granted by Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to ILUVIEN.For treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.Polish approval marks 17thand final country authorization to be granted through the European Repeat-Use application procedure.  Full Article

More From Around the Web

BRIEF-Alimera Sciences and Knight Therapeutics file new drug submission for iluvien in Canada

* Alimera Sciences and Knight Therapeutics announce filing of new drug submission for iluvien in Canada